PRGO Perrigo Company
- Price as of: Dec 19, 10:24 PM EST
- Drug related products
PRGO Stock Dividend DataAdd PRGO to Watchlist
PRGO Dividend Yield & Stock Price History
PRGO Dividend Payout History
PRGO Daily Snapshot
- Quote Time:
- Dec 19, 10:24 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $166.02 - $171.57
- Previous Close:
- 52 Week Low / High:
- $125.37 - $171.57
- Percent Off 52 Week High:
PRGO Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for PRGO||11.8%||9.1%||11 years|
PRGO Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
PRGO Company Profile
Perrigo Company- (PRGO)-develops, manufactures, and distributes over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and consumer products worldwide. The company operates in three segments: Consumer Healthcare, Prescription (Rx) Pharmaceuticals, and Active Pharmaceutical Ingredients (API). The company was founded in 1887 and is based in Allegan, Michigan.
Perrigo Company News
Feb 18, 2014These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Perrigo Company...
Feb 6, 2014These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Allstate (ALL) -...
Perrigo Company Q4 Profit Rises on 16% Higher Revenues; Adjusted EPS Tops Views, But Revenues Miss (PRGO)Aug 15, 2013Before the opening bell on Thursday, pharmaceutical products manufacturer Perrigo Company (PRGO) reported a rise in its fourth quarter net income on a rise in revenues. Though the company's adjusted earnings topped estimates, its revenues missed Wall Street expectations. The Allegan, Michigan-based company posted a fourth quarter net income of $118.5 million, or $1.25 per share, up from $107.1 million, or $1.14 per share, in the same period a year ago. Excluding charges, Perrigo's adjusted net income from continuing operations for the quarter came in at $148.1 million, or $1.57 per share. According to analysts polled by Thomson Reuters, the company was expected to earn $1.56 per share in the quarter. Perrigo's quarterly net sales were $967.2 million, up about 16% from $831.8 million in revenues posted in the fourth quarter of 2012. However, analysts were expecting the company to see $999.08 million in revenues for the most recent quarter. Looking ahead and excluding the potential impact of the acquisition of Elan, Perrigo expects to report earnings between $5.51 and $5.76 per share in fiscal 2014, with adjusted earnings coming in between $6.35 and $6.60 per share. Perrigo shares were down $4.42, or 3.50%, during pre-market trading on Thursday. The stock is up 21.52% year-to-date. The Bottom Line Shares of Perrigo (PRGO) offer a 0.28% dividend yield based on last night's closing price of $126.42 and the company's annualized dividend payout of 36 cents per share. Perrigo Company (PRGO) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Perrigo Q2 Profit Rises; Adjusted Net and Revenue Beat Wall Street View (PRGO)Feb 1, 2013On Friday drug company Perrigo (PGRO) said that it saw a 6% increase to its second quarter earnings on higher revenues, with adjusted net income and revenue beating Wall Street expectations. The Allegan, Michigan-based company reported a fiscal second quarter net income of $105.95 million, or $1.12 per share, up from $99.74 million, or $1.06 per share, earned in the same quarter a year earlier. Adjusted earnings increased to $1.36 per share from $1.20. Analysts, according to Thomson Reuters, were expecting EPS to be $1.31. The company's net sales were up to $882.96 million from $838.17 million last year. This just beat the analyst estimate of $881.84 million in revenue for the quarter. Also announced on Friday was that Perrigo signed a agreement to acquire leading pet health product company Velcera for $160 million in cash. Looking ahead to fiscal 2013, the company is expecting EPS to be between $5.45 and $5.65 while analysts foresee EPS at $5.54. Perrigo shares were up $4.99, or +4.96%, during pre-market trading on Friday. The stock is up +4.59% over the past year. The Bottom Line Shares of Perrigo (PRGO) have a dividend yield of 0.36% based on last night's closing price of $100.51. Perrigo Company (PRGO) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Nov 7, 2012The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts Aaron's Inc. (AAN) has...
Oct 26, 2011The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts Barrick Gold (ABX) has...
Oct 27, 2010The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts Alliance Resource Partners...
Oct 29, 2009The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts American Physicians Capital...
Feb 3, 2009These were some of the biggest dividend stock performers on the upside and the downside in today's stock market action. Highlights DR Horton...
Perrigo Company's Generic Drug Profits Jump (PRGO)Aug 18, 2008Perrigo Company (PRGO) reported a 34 percent jump in revenue for its latest quarter, to $500.2 million. The company, which markets over-the-counter and prescription drugs, was helped by strong sales in its consumer healthcare segment. Consumer Healthcare segment net sales for the quarter were a record $375 million, up $117 million, or 46 percent, compared with $257 million last year. The sales increase included $75 million in new product revenue, led by Omeprazole and Cetirizine, as well as strong sales in the cough/cold, analgesic and smoking cessation product categories. The Bottom Line The company's 2009 outlook of $1.90 to $1.98 per share, is just about where the consensus is right now. From a valuation standpoint, 19 times earnings is about average for this sector. The dividend yield of .57% (based on Friday's closing stock price of $35.37), is not super attractive. The stock is up about 70% in the last 4 years, so we think the growth side of the story bears watching. For now, we will monitor the news flow, but hold off putting it on our "Recommended" list. Perrigo Company (PRGO) is not a recommended dividend stock at this time, holding a Dividend.com rating of 3.1 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks as well as a detailed explanation of our ratings system here.Expand to read the full story